Found: 56
Select item for more details and to access through your institution.
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 4, p. 3062, doi. 10.3390/ijms24043062
- By:
- Publication type:
- Article
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 4, p. 837, doi. 10.3390/ijms18040837
- By:
- Publication type:
- Article
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-24644-1
- By:
- Publication type:
- Article
Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2023, v. 15, n. 1, p. 1, doi. 10.4084/MJHID.2023.013
- By:
- Publication type:
- Article
Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2023, v. 15, n. 1, p. 1, doi. 10.4084/MJHID.2023.051
- By:
- Publication type:
- Article
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2022, v. 14, n. 1, p. 1, doi. 10.4084/MJHID.2022.041
- By:
- Publication type:
- Article
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2013, v. 5, n. 1, p. 1, doi. 10.4084/MJHID.2013.032
- By:
- Publication type:
- Article
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 954, doi. 10.1111/bjh.15655
- By:
- Publication type:
- Article
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 5, p. 741, doi. 10.1111/bjh.14621
- By:
- Publication type:
- Article
Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 11, p. 3015, doi. 10.1007/s00277-023-05384-2
- By:
- Publication type:
- Article
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1275, doi. 10.1007/s00277-022-04815-w
- By:
- Publication type:
- Article
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
- Published in:
- Annals of Hematology, 2015, v. 94, n. 5, p. 771, doi. 10.1007/s00277-015-2341-z
- By:
- Publication type:
- Article
Extensive toxic epidermal necrolysis following brentuximab vedotin administration.
- Published in:
- 2015
- By:
- Publication type:
- Letter
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 10, p. 1765, doi. 10.1007/s00277-014-2117-x
- By:
- Publication type:
- Article
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.
- Published in:
- 2014
- By:
- Publication type:
- Letter
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 9, p. 1509, doi. 10.1007/s00277-014-2080-6
- By:
- Publication type:
- Article
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 8, p. 1413, doi. 10.1007/s00277-014-2053-9
- By:
- Publication type:
- Article
In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 7, p. 1776, doi. 10.3390/jcm11071776
- By:
- Publication type:
- Article
Acute leukemia diagnosis during the COVID-19 pandemic.
- Published in:
- Panminerva Medica, 2023, v. 65, n. 1, p. 93, doi. 10.23736/S0031-0808.21.04618-8
- By:
- Publication type:
- Article
Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience.
- Published in:
- Cancers, 2022, v. 14, n. 22, p. 5640, doi. 10.3390/cancers14225640
- By:
- Publication type:
- Article
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4897, doi. 10.3390/cancers14194897
- By:
- Publication type:
- Article
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1083, doi. 10.3390/cancers13051083
- By:
- Publication type:
- Article
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness.
- Published in:
- Cancers, 2020, v. 12, n. 1, p. 120, doi. 10.3390/cancers12010120
- By:
- Publication type:
- Article
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1417, doi. 10.3390/cancers11101417
- By:
- Publication type:
- Article
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1373, doi. 10.3390/cancers11091373
- By:
- Publication type:
- Article
Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
- Published in:
- Life Science Alliance, 2022, v. 5, n. 12, p. 1, doi. 10.26508/lsa.202201590
- By:
- Publication type:
- Article
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.752192
- By:
- Publication type:
- Article
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 6, p. 643, doi. 10.1111/ejh.12674
- By:
- Publication type:
- Article
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 4, p. 344, doi. 10.1111/ejh.12595
- By:
- Publication type:
- Article
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
- Published in:
- European Journal of Haematology, 2015, v. 95, n. 1, p. 52, doi. 10.1111/ejh.12476
- By:
- Publication type:
- Article
Evaluation of the prognostic relevance ofl-selectin and ICAM1 expression in myelodysplastic syndromes.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 2, p. 107, doi. 10.1111/j.1600-0609.2007.00986.x
- By:
- Publication type:
- Article
Consolidation and Maintenance Immunotherapy With Rituximab Improve Clinical Outcome in Patients With B-cell Chronic Lymphocytic Leukemia.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 1, p. 119, doi. 10.1002/cncr.23144
- By:
- Publication type:
- Article
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‐70‐negative chronic lymphocytic leukemiaPresented in part at the 46th Annual Meeting of the American Society of Hematology, San Diego, California, December 4–7, 2004.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 12, p. 2743, doi. 10.1002/cncr.21535
- By:
- Publication type:
- Article
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
Opioids in pain management of blood-related malignancies.
- Published in:
- Annals of Hematology, 2006, v. 85, n. 8, p. 489, doi. 10.1007/s00277-005-0062-4
- By:
- Publication type:
- Article
MRD in AML: The Role of New Techniques.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00655
- By:
- Publication type:
- Article
FCγ Chimeric Receptor-engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
- Published in:
- Frontiers in Immunology, 2017, v. 8, p. 1, doi. 10.3389/fimmu.2017.00457
- By:
- Publication type:
- Article
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Longitudinal detection of <italic>DNMT3A</italic><sup>R882H</sup> transcripts in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 5, p. E120, doi. 10.1002/ajh.25061
- By:
- Publication type:
- Article
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 5, p. E80, doi. 10.1002/ajh.23966
- By:
- Publication type:
- Article
Minimal residual disease as biomarker for optimal biologic dosing of ARA- C in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 2, p. 125, doi. 10.1002/ajh.23893
- By:
- Publication type:
- Article
Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 5, p. 565, doi. 10.1002/ajh.23677
- By:
- Publication type:
- Article
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
- Published in:
- Leukemia Research & Treatment, 2013, p. 1, doi. 10.1155/2013/705714
- By:
- Publication type:
- Article
Azacitidine for the treatment of patients with acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 4, p. 1014, doi. 10.1002/cncr.26354
- By:
- Publication type:
- Article
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes: A Retrospective Study of 74 Patients Enrolled in an Italian Named Patient Program.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 6, p. 1485, doi. 10.1002/cncr.24894
- By:
- Publication type:
- Article
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2010, v. 149, n. 3, p. 383, doi. 10.1111/j.1365-2141.2010.08098.x
- By:
- Publication type:
- Article
research paper CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 2, p. 203, doi. 10.1111/j.1365-2141.2004.04883.x
- By:
- Publication type:
- Article